ConnectOne Bancorp, Inc. Reports a 14.3% Increase in First Quarter Net Income
Apr 27, 2017 11:02 am UTC| Business
ENGLEWOOD CLIFFS, N.J., April 27, 2017 -- ConnectOne Bancorp, Inc. (Nasdaq:CNOB) (the “Company” or “ConnectOne”), parent company of ConnectOne Bank (the “Bank”), today reported net income of $11.9 million for the first...
Antares Pharma to Present at the Deutsche Bank Securities, Inc. 42nd Annual Health Care Conference
Apr 27, 2017 11:02 am UTC| Business
EWING, N.J., April 27, 2017 -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert Apple, President and Chief Executive Officer, will present at the Deutsche Bank Securities, Inc. 42nd Annual Health Care...
Antares Pharma to Present at the Deutsche Bank Securities, Inc. 42nd Annual Health Care Conference
Apr 27, 2017 11:02 am UTC| Business
EWING, N.J., April 27, 2017 -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert Apple, President and Chief Executive Officer, will present at the Deutsche Bank Securities, Inc. 42nd Annual Health Care...
Antares Pharma to Present at the Deutsche Bank Securities, Inc. 42nd Annual Health Care Conference
Apr 27, 2017 11:02 am UTC| Business
EWING, N.J., April 27, 2017 -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert Apple, President and Chief Executive Officer, will present at the Deutsche Bank Securities, Inc. 42nd Annual Health Care...
Apr 27, 2017 11:02 am UTC| Business
WALTHAM, Mass., April 27, 2017 -- Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), today announced the expansion of ENCORE 601/KEYNOTE 142, the ongoing Phase 2 clinical collaboration with a subsidiary of Merck, known as MSD...
Apr 27, 2017 11:02 am UTC| Business
WALTHAM, Mass., April 27, 2017 -- Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), today announced the expansion of ENCORE 601/KEYNOTE 142, the ongoing Phase 2 clinical collaboration with a subsidiary of Merck, known as MSD...
Apr 27, 2017 11:02 am UTC| Business
WALTHAM, Mass., April 27, 2017 -- Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), today announced the expansion of ENCORE 601/KEYNOTE 142, the ongoing Phase 2 clinical collaboration with a subsidiary of Merck, known as MSD...